Aberrant expression of SPAG6 and NM23 predicts poor prognosis of human osteosarcoma

Bao, Zhengqi; Zhu, Ruizhi; Fan, Huagang; Ye, Yuchen; Li, Tian; Chai, Dongqi

doi:10.3389/fgene.2022.1012548

Cited by 2 publications

(1 citation statement)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Initially identified in human testicular tissue, SPAG6 governs sperm flagella motility and germ cell maturation ( 9 ). Recent investigations have unveiled the association of SPAG6 with tumorigenesis and progression ( 10 - 14 ). Nonetheless, limited studies have examined the precise mechanisms underlying SPAG6 ’s involvement in cancer and immunity.…”

Section: Introductionmentioning

confidence: 99%

A comprehensive pan-cancer analysis revealing SPAG6 as a novel diagnostic, prognostic and immunological biomarker in tumor

Li,

Wang,

et al. 2024

Gland Surg

View full text Add to dashboard Cite

Background There have been studies on the role of sperm-associated antigen 6 (SPAG6 ) in cytoskeleton formation and growth cone stability, but it is also unknown how spag6 affect tumor growth and development. The aim of this study was to clarify the role of SPAG6 in pan-cancer, with some findings about thyroid carcinoma (THCA) validated through experiments. Methods We examined the role of SPAG6 in pan-cancer, with the data being collected from databases. Further analysis was conducted to assess its correlations with prognosis, gene heterogeneity, stemness, and tumor immunity. The interacting proteins of SPAG6 were also identified, and gene ontology enrichment analysis was performed to determine its biological function. We preliminarily confirmed the role of SPAG6 via in vitro experiments and immunofluorescence staining. Results This study found that SPAG6 expression was differentially expressed in cancers and at various tumor stages and grades. In stomach and esophageal carcinoma (STES), stomach adenocarcinoma (STAD), kidney renal clear cell carcinoma (KIRC), lung squamous cell carcinoma (LUSC), and adrenocortical carcinoma (ACC), SPAG6 expression was correlated with gender. SPAG6 expression was also found to be correlated with prognostic value, with low expression being associated with poor prognosis. Furthermore, SPAG6 expression was positively linked with immune-related cells in HNSC, chemokine receptors in LUSC, and immune checkpoint genes in THCA. Furthermore, SPAG6 overexpression suppressed the malignant phenotypes of THCA cells, manifested by slower proliferation and decreased migration. The different SPAG6 expression in THCA led to different malignant phenotypes, which are involved in the upregulation of DNA repair, MYC targets, peroxisome, and G2M checkpoint. Conclusions SPAG6 plays a significant role as an oncogene and can be used as a marker to predict the prognosis of cancer. SPAG6 influences both the tumor immune infiltration and microenvironment, making it a promising immunotherapeutic target for tumor therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

A comprehensive pan-cancer analysis revealing SPAG6 as a novel diagnostic, prognostic and immunological biomarker in tumor

Li,

Wang,

et al. 2024

Gland Surg

View full text Add to dashboard Cite

show abstract

Germline genetic variants and pediatric rhabdomyosarcoma outcomes: a report from the Children’s Oncology Group

Martin-Giacalone

Richard

Scheurer

et al. 2023

JNCI: Journal of the National Cancer Institute

View full text Add to dashboard Cite

Background Relative to other pediatric cancers, survival for rhabdomyosarcoma has not improved in recent decades, suggesting the need to enhance risk stratification. Therefore, we conducted a genome-wide association study for event-free survival (EFS) and overall survival (OS) to identify genetic variants associated with outcomes in individuals with rhabdomyosarcoma. Methods The study included 920 individuals with newly diagnosed rhabdomyosarcoma who were enrolled on Children’s Oncology Group protocols. To assess the association of each single nucleotide polymorphism (SNP) with EFS and OS, we estimated hazard ratios (HR) and 95% confidence intervals (CI) using multivariable Cox proportional hazards models, adjusted for clinical covariates. All statistical tests were two sided. We also performed stratified analyses by histological subtype (alveolar and embryonal rhabdomyosarcoma) and carried out sensitivity analyses of statistically significant SNPs by PAX3/7-FOXO1 fusion status and genetic ancestry group. Results We identified that rs17321084 was associated with worse EFS (HR = 2.01, 95% CI = 1.59-2.53, P = 5.39x10-9) and rs10094840 was associated with worse OS (HR = 1.84, 95% CI = 1.48-2.27, P = 2.13x10-8). Using publicly available data, we found that rs17321084 lies in a binding region for transcription factors GATA2 and GATA3, and rs10094840 is associated with SPAG1 and RNF19A expression. We also identified that CTNNA3 rs2135732 (HR = 3.75, 95% CI = 2.34-5.99, P = 3.54x10-8) and MED31 rs74504320 (HR = 3.21, 95% CI = 2.12-4.86, P = 3.60x10-8) were associated with worse OS among individuals with alveolar rhabdomyosarcoma. Conclusions We demonstrated that common germline variants are associated with EFS and OS among individuals with rhabdomyosarcoma. Additional replication and investigation of these SNP effects may further support their consideration in risk stratification protocols.

show abstract

Aberrant expression of SPAG6 and NM23 predicts poor prognosis of human osteosarcoma

Cited by 2 publications

References 39 publications

A comprehensive pan-cancer analysis revealing SPAG6 as a novel diagnostic, prognostic and immunological biomarker in tumor

A comprehensive pan-cancer analysis revealing SPAG6 as a novel diagnostic, prognostic and immunological biomarker in tumor

Germline genetic variants and pediatric rhabdomyosarcoma outcomes: a report from the Children’s Oncology Group

Contact Info

Product

Resources

About